- Home
- Products
- Customized ADCs
- CD44
- Anti-CD44 (Bivatuzumab)-MC-MMAF ADC
Anti-CD44 (Bivatuzumab)-MC-MMAF ADC (CAT#: ADC-W-2544)
This ADC product is comprised of an anti-CD44 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD44
- Alternative Names
- CD44; CD44 molecule (Indian blood group); CD44 antigen (homing function and Indian blood group system) , MDU2, MDU3, MIC4; CD44 antigen; CD44R; chondroitin sulfate proteoglycan 8; CSPG8; HCELL; hematopoietic cell E and L selectin ligand; IN; MC56; Pgp1; epican; Hermes antigen; hyaluronate receptor; phagocytic glycoprotein 1; heparan sulfate proteoglycan; cell surface glycoprotein CD44; extracellular matrix receptor III; GP90 lymphocyte homing/adhesion receptor; hematopoietic cell E- and L-selectin ligand; homing function and Indian blood group system; LHR; MDU2; MDU3; MIC4; CDW44; HUTCH-I; ECMR-III; MGC10468;
- Target Entrez Gene ID
- 960
- Target UniProt ID
- P16070
- Overview
- The protein encoded by this gene is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. It is a receptor for hyaluronic acid (HA) and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full length nature of some of these variants has not been determined. Alternative splicing is the basis for the structural and functional diversity of this protein, and may be related to tumor metastasis.
- Overview
- Humanized Anti-CD44 IgG1 antibody, Bivatuzumab
- Generic name
- Bivatuzumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC (CAT#: ADC-W-572)
- Anti-CD6 (Itolizumab)-SMCC-DM1 ADC (CAT#: ADC-W-944)
- Anti-PCSK9 (Bococizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2231)
- Anti-CD19 (Denintuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-2517)
- Anti-PDGFR (Tovetumab)-SPDB-DM4 ADC (CAT#: ADC-W-1713)
- Anti-FZD1 (Vantictumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1183)
- Anti-ERBB2 (Trastuzumab)-NGM-doxorubicin ADC (CAT#: ADC-W-412)
- Anti-EGFR (Nimotuzumab)-MC-MMAF ADC (CAT#: ADC-W-1060)
- Anti-CD37 (Otlertuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-821)
- Anti-C-kit-SMCC-DM1 ADC-2 (CAT#: ADC-W-070)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2544. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2543 | Anti-CD44 (Bivatuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2546 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-541 | Anti-CD44-DM1 ADC | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | |
| ADC-W-2545 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-515 | Anti-EGFR-Mc-MMAF ADC-5 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-517 | Anti-TM4SF1-Mc-LP2 ADC-1 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2539 | Anti-CD33 (Gemtuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.